Abstract

A SYSTEMATIC REVIEW ON SAFETY AND EFFICACY OF DABIGATRAN VS RIVAROXABAN

V. Sanghavi*, Gayathri M., Ramya V., Pavithra G., Merlin Jose and Monica B.

.

Abstract

Anticoagulants are the primary treatment for patients suffering from atrial fibrillation (AF) and are used to prevent stroke and systemic embolism. Direct factor Xa inhibitors, such as Rivaroxaban, are taken orally, whereas direct thrombin inhibitors, such as Dabigatran, are given intravenously. Compared to Rivaroxaban, Dabigatran (150 mg BID) significantly reduced the risk of stroke and systemic embolism, as well as hemorrhagic stroke. When compared to Rivaroxaban, Dabigatran (110 mg BID) was associated with lower significant hemorrhage and cerebral bleeding. Major risk bleeds were significantly higher with Rivaroxaban than with Dabigatran, as were all-cause mortality and gastrointestinal bleeding.

Keywords: Rivaroxaban, Dabigatran, Atrial Fibrillation, Stroke.